Paremyd

Generic name:hydroxyamphetamine hydrobromide and tropicamide
Dosage form: ophthalmic solution
Drug class:Mydriatics

Medically reviewed by Drugs.com. Last updated on Feb 1, 2022.

1%/0.25%
Sterile

Rx only

Paremyd Description

Paremyd® sterile ophthalmic solution is a topical mydriatic combination product for ophthalmic use.

STRUCTURAL FORMULAE

CHEMICAL NAME
Hydroxyamphetamine hydrobromide: Phenol, 4-(2-aminopropyl)-, hydrobromide
Tropicamide: Benzeneacetamide, N-ethyl-α-(hydroxymethyl)-N-(4-pyridinylmethyl)-

CONTAINS
Actives: Hydroxyamphetamine hydrobromide, USP.....1.0%
Tropicamide, USP.....0.25%
Preservative: Benzalkonium Chloride 0.005%
Inactives: Edetate Disodium 0.015%, Sodium Chloride; Hydrochloric Acid and/or Sodium Hydroxide may be added to adjust pH (4.2 to 5.8 during its shelf life), and Water for Injecton. The osmolality of Paremyd® is approximately 307 mOsm/l.

Paremyd - Clinical Pharmacology

Paremyd® Solution combines the effects of the adrenergic agent, hydroxyamphetamine hydrobromide, and the anticholinergic agent, tropicamide.

Hydroxyamphetamine hydrobromide is an indirectly-acting sympathomimetic agent which, when applied topically to the eye, causes the release of endogenous norepinephrine from intact adrenergic nerve terminals resulting in mydriasis. Since hydroxyamphetamine hydrobromide has little or no direct activity on the receptor site, dilation does not usually occur if there is damage to the presynaptic nerve terminal, e.g., Horner's Syndrome. However, it is not known whether damage to the presynaptic nerve terminal will influence the extent of mydriasis produced by Paremyd®. Hydroxyamphetamine hydrobromide has minimal cycloplegic action.

Tropicamide is a parasympatholytic agent which, when applied topically to the eye, blocks the responses of the sphincter muscle of the iris and the ciliary muscle to cholinergic stimulation, producing dilati